Home Featured

Featured

How Do You Find the Right Facilitator? The Art of Matchmaking in Psychedelic Healing

Pα+ Psychedelic Bulletin #186: As Trump Takes Office, Impact on Psychedelics Field Remains Unclear; The Jurvetsons Discuss Psychedelics at DLD; GH Shares PoC Data

Bifurcation Squared: Compass Lobbies for Narrow Rescheduling in Colorado, Virginia; Pushes Back on State Policy Reforms

Is the DEA Sabotaging Psychedelic Research? Inside the Push to Schedule DOI and DOC

Psychedelics in 2024: From Hype to Hard Realities

mpathic Co-Founder Danielle Schlosser on AI Oversight of Psychedelics Trials

Patent Analysis: Lykos Suffers Blow from USPTO As All Patent Claims...

Kama Flight: The Healing Power of Somatic Movement, Communication, and Trust

PsychedeliCare Launches First European Citizens’ Initiative Demanding Political Action on Psychedelic-Assisted...

Pα+ Psychedelic Bulletin #185: Joe Rogan on Ibogaine; Wisconsin Medicaid to...

Billionaire Investor Antonio Gracias Plots $100M Lykos Takeover with Doblin’s Backing

Can Legalization Serve the Greater Good? The Ethical Challenges of Psychedelic...

From Fringe to Focus: APA’s American Journal of Psychiatry Publishes Special...

Natural Medicine Advisory Bulletin 15: A Duplicitous December

Pot for the People: Debunking Cannabis Myths and Empowering Consumers

12 3...279 Page 1 of 279

How Do You Find the Right Facilitator? The Art of Matchmaking...

Pα+ Psychedelic Bulletin #186: As Trump Takes Office, Impact on Psychedelics...

Bifurcation Squared: Compass Lobbies for Narrow Rescheduling in Colorado, Virginia; Pushes...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.